MLC1501
Phase 2Small molecule
MLC1501 is one of 27 small molecule programs targeting Stroke. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Zometa
PfizerPreclinical
Folvite
Eli LillyPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Direct Anticoagulant
BayerPreclinical
MLC1501
MMoleac Pte Ltd.
Phase 2
Inderal
Mylan Pharmaceuticals IncPreclinical
Botulinum Toxin a
GSKPreclinical
Anticoagulant
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MLC1501. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMoleac Pte Ltd.